Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERd in newly diagnosed multiple myeloma
NCT02843074Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2016
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Sep 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02843074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843074.